Patient Advocacy and Changing Paradigm in Drug Access

Submitted by sys1 on Fri, 11/11/2016 - 12:53
International Journal of Medicine and Public Health,2016,6,4,154-159.
Published:November 2016
Type:Review Article

Patient Advocacy and Changing Paradigm in Drug Access

Amit Dang1,Vallish BN 2

1Founder and CEO, MarksMan Healthcare Solutions, 1st Floor, Plot No. 6, Sector 12A, Kopar Khairane, Navi Mumbai, Maharashtra - 400709, India.

2Assistant Professor, Department of Pharmacology, Velammal Medical College Hospital and Research Institute, Anuppanadi, Madurai - 625009. TN, India.


Background: In the process of drug development and drug approval, the pharmaceutical industry is challenged with increasing cost constraints, a growing need for real-world evidence and heavier regulatory scrutiny. Patient advocacy groups can be a valuable partner to the pharmaceutical industry in speeding up drug access. Patient advocates possess practical rather than purely scientific knowledge that is valuable for both drug development and drug approval. It was recognized quite early the patient advocacy groups and the pharmaceutical industry have similar goals. This understanding resulted in supporting patient involvement across the entire process of drug development, from discovery to USFDA approval for marketing. Support received by the patient advocacy groups include fundraising for research and development, organizing patients to expedite clinical trials, lobbying government and payer organizations to create public awareness, building support for research funding, and so on. Patient advocacy groups also back research for “orphan” diseases where there is a desperate need for new therapies. The recent success of Vertex and Sprout Pharmaceutical highlights the power of the patient voice in healthcare decision-making especially for orphan diseases. Conclusion: Working with patient groups can thus lead to a win-win situation for both the FDA and pharmaceutical industry.

Arnstein’s ladder of citizen participation2

Post Categories: